Spleen cell dialyzable extracts (SCDE) mediated immunotherapy for patients with myasthenia gravis.
We studied 14 cases of myasthenia gravis (MG) with regard to their anti-acetylcholine receptor antibody (AChR-Ab) production, peripheral blood CD4+/CD8+ ratio, and responses of peripheral lymphocytes to PHA and PWM stimulations. We found that the clinical severity was not proportional to AChR-Ab level in serum in terms of whole myasthenic population, whereas in one individual patient there was a close correlation between clinical severity and the AChR-Ab level in serum. The CD4+/CD8+ ratio in myasthenic patients was significantly higher than that of normal controls. The responses of T- and B-cells to mitogenic stimulations were impaired in myasthenic patients. The immune abnormalities found in the majority of the patients were restored to about normal after spleen cell dialyzable extracts (SCDE) therapy was applied to all patients. The results implicated that SCDE, working as an immunomodulator, could serve as a promising agent to normalize the abnormal immune functions of MG patients or other autoimmune diseases.